Integra LifeSciences IART Allowance for Doubtful Accounts Receivable (Current)
Allowance for Doubtful Accounts Receivable (Current) at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.
The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Integra LifeSciences's allowance for doubtful accounts receivable (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Integra LifeSciences's allowance for doubtful accounts receivable (current)?
- Integra LifeSciences (IART) reported allowance for doubtful accounts receivable (current) of $7.41M in Q1 2026.
- How has Integra LifeSciences's allowance for doubtful accounts receivable (current) changed year-over-year?
- Integra LifeSciences's allowance for doubtful accounts receivable (current) increased by 14.3% year-over-year, from $6.48M to $7.41M.
- What is the long-term trend for Integra LifeSciences's allowance for doubtful accounts receivable (current)?
- Over 5 years (2020 to 2025), Integra LifeSciences's allowance for doubtful accounts receivable (current) has grown at a 2.3% compound annual growth rate (CAGR), from $6.44M to $7.23M.
- What does allowance for doubtful accounts receivable (current) mean?
- This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.